These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30642372)

  • 1. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
    Sun Y; Yang L; Hao X; Liu Y; Zhang J; Ning Z; Shi Y
    J Hematol Oncol; 2019 Jan; 12(1):9. PubMed ID: 30642372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
    Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
    Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
    Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
    Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.
    Sun Y; Niu W; Du F; Du C; Li S; Wang J; Li L; Wang F; Hao Y; Li C; Chi Y
    J Hematol Oncol; 2016 Oct; 9(1):105. PubMed ID: 27716285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
    Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
    Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.
    Doi T; Matsubara N; Kawai A; Naka N; Takahashi S; Uemura H; Yamamoto N
    Invest New Drugs; 2020 Aug; 38(4):1175-1185. PubMed ID: 31820255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.
    Dittrich C; Fridrik MA; Koenigsberg R; Lee C; Goeldner RG; Hilbert J; Greil R
    Invest New Drugs; 2015 Apr; 33(2):409-22. PubMed ID: 25529193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
    Dees EC; Infante JR; Cohen RB; O'Neil BH; Jones S; von Mehren M; Danaee H; Lee Y; Ecsedy J; Manfredi M; Galvin K; Stringer B; Liu H; Eton O; Fingert H; Burris H
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):945-54. PubMed ID: 20607239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
    Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
    Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
    Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
    Hollebecque A; Deutsch E; Massard C; Gomez-Roca C; Bahleda R; Ribrag V; Bourgier C; Lazar V; Lacroix L; Gazzah A; Varga A; de Baere T; Beier F; Kroesser S; Trang K; Zenke FT; Klevesath M; Soria JC
    Invest New Drugs; 2013 Dec; 31(6):1530-8. PubMed ID: 24077982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Ameratunga M; Braña I; Bono P; Postel-Vinay S; Plummer R; Aspegren J; Korjamo T; Snapir A; de Bono JS
    Br J Cancer; 2020 Dec; 123(12):1730-1736. PubMed ID: 32989226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.